Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the best growth stocks to invest in for the next 5 years. Gautam Patel, the director of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), sold 94,906 shares of Class A Common Stock, worth around $761,146, on June 16, 2025. The prices fluctuated between $8.00 and $8.05 per share, while the current trading price stands at $7.92.

As a result of the transaction, Patel’s stake now amounts to 1,609,144 shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX). The sale was executed automatically in accordance with a pre-determined trading plan adopted on August 15, 2024, and in compliance with Rule 10b5-1(c). In general, analysts remain optimistic regarding the stock, with price targets ranging between $11 and $12 per share.

Just recently, analysts at Goldman Sachs reviewed the generic drug industry and initiated coverage on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a positive outlook. The reasons cited were many, from current portfolio changes favoring higher-value products to the company’s track record of business execution. With a 12-month price target of $12, the analyst supported the potential upside of over 50%.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered in Bridgewater, New Jersey, is a leading biopharmaceutical company that develops and markets generics, injectables, biosimilars, and specialty branded pharmaceutical products. Founded in 2002, the company operates through three main segments: Affordable Medicines, Specialty, and AvKARE. The giant is committed to advancing innovation in healthcare.

While we acknowledge the potential of AMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.